Also, the study by Liu and colleagues in 2022 aimed to review the current understanding of the role of antibodies and inflammatory agents as CHI3L1 in the pathophysiology of MS, their clinical relevance, and their potential as biomarkers for the disease. This evidence concerns the gene CHI3L1 and myeloid sarcoma.